<html><head></head><body><h1>In-111 DTPA</h1><p class="drug-subtitle"><b>Generic Name:</b> indium in-111 pentetate disodium<br/>
<b>Dosage Form:</b> intrathecal solution<br/></p><ul class="nav-tabs nav-tabs-collapse nav-tabs-pill">
<li>Side Effects</li>
<li><b class="nav-item here">Professional</b></li>
<li>Interactions</li>
<li class="nav-more">
More&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;svg aria-hidden="true" class="ddc-icon ddc-icon-down" focusable="false" height="16" viewBox="0 0 24 24" width="16" xmlns="http://www.w3.org/2000/svg"&gt;&lt;path d="M18.5 7.94L19.56 9 12 16.56 4.44 9 5.5 7.94l6.5 6.5z"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/body&gt;&lt;/html&gt;
</li>
</ul><p class="disclaimer">Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.</p><ul>
<li>Description</li>
<li>Indications and Usage</li>
<li>Clinical Pharmacology</li>
<li>Contraindications</li>
<li>Dosage and Administration</li>
</ul><h2>In-111 DTPA Description</h2><p class="First">In-111 DTPA is supplied as a sterile, pyrogen-free, isotonic, aqueous solution that is  buffered to pH 7 to 8. At calibration time, each milliliter contains 2.5 mCi of Pentetate Indium Disodium In-111 (no carrier-added) and sodium bicarbonate for pH adjustment.</p><h2>CHARACTERISTICS</h2><p class="First">Indium 111 decays by electron capture with a physical half-life of 67.9 hour. The energies of the photons that are useful for detection and imaging studies are:</p><p><span class="Bold">Radiation Mean % Disintegration Mean Energy (keV)</span></p><p>Gamma-2 90.2 171.3</p><p>Gamma-3 94.0 245.4</p><h2>Indications and Usage for In-111 DTPA</h2><p class="First">In-111 DTPA is indicated for use in  radionuclide cisternography</p><h2>In-111 DTPA - Clinical Pharmacology</h2><p class="First">After intrathecal administration, the In-111 DTPA is absorbed from the subarachnoid space and the remainder flows superiorly to the basal cisterns within 2 to 4 hours and subsequently will be apparent in the Sylvian cisterns, the interhemispheric cisterns, and over the cerebral convexities. In normal individuals, the it  will have ascended to the parasagittal region within 24 hours with simultaneous partial or complete clearance of activity from the basal cisterns and Sylvian regions. In contrast to air, In-111 DTPA does not normally enter the cerebral ventricles</p><h2>Contraindications</h2><p class="First">There are no known contraindications</p><h2>In-111 DTPA Dosage and Administration</h2><p class="First">Extreme care must be exercised to assure aseptic conditions in intrathecal injections. The maximum recommended intrathecal dose in the average patient (70kg) is 18.5 megabecquerels (500 microcuries). The patient dose should be measured by a suitable radioactivity calibration system immediately prior to administration. Parenteral drug preparations should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.</p><h3>Storage and Handling</h3><p class="First">Store vial in its lead shield at a temperature of 5-30ยบ C. Do not freeze</p><h2>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</h2><p class="First"><span class="Bold">Figure 1</span></p><h2>More about indium pentetate in-111</h2><ul class="more-resources-list more-resources-list-general">
<li>Side Effects</li>
<li>Drug Interactions</li>
<li>Drug class: diagnostic radiopharmaceuticals</li>
</ul><p class="ddc-disclaimer-link">Medical Disclaimer</p></body></html>